GBA1 and Gaucher disease: The only registered drug that is promising for the treatment of patients with NPC is N-butyldeoxynojirimycin (miglustat), which was initially approved for the treatment of Gaucher disease, a hereditary deficiency of lysosomal glucocerebrosidase.